Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
112 hedge funds and large institutions have $225M invested in Y-mAbs Therapeutics in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 11 closing their positions.
525% more call options, than puts
Call options by funds: $50K | Put options by funds: $8K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
26% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 31
7% more funds holding
Funds holding: 105 → 112 (+7)
6.55% more ownership
Funds ownership: 57.75% → 64.3% (+6.5%)
33% less capital invested
Capital invested by funds: $339M → $225M (-$113M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$6.98M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$2.44M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$1.83M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$1.66M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.5M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.1M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.39M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.24M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.15M |
YMAB Hedge Fund Activity: Q4 2024 in Review
112 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2024, worth a combined $225M — down 33% from $339M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new YMAB positions and 11 closed out — a net gain of 7 holders — while 39 added to existing stakes and 31 trimmed.
The largest buyer was Caligan Partners, adding an estimated $6.98M. The largest seller was Cormorant Asset Management, cutting an estimated $12.5M.
- 112 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2024, up from 105 in Q3 2024.
- Funds reported $225M of Y-mAbs Therapeutics stock for Q4 2024, down 33% quarter-over-quarter.
- 18 funds opened new Y-mAbs Therapeutics positions in Q4 2024 and 11 closed out, a net change of +7 holders.
- The largest Y-mAbs Therapeutics buyer in Q4 2024 was Caligan Partners, an estimated $6.98M added.
- The largest Y-mAbs Therapeutics seller in Q4 2024 was Cormorant Asset Management, an estimated $12.5M sold.
Based on aggregated 13F filings for Q4 2024.